Background
Methods
Study population
Intervention
Data collection
Statistical analyses
Ethical approval
Results
Demographics and baseline characteristics
Variable | High-dose group (21 patients) | Low-dose group (27 patients) | P-value |
---|---|---|---|
Age, years, mean ± SD | 74.90 ± 2.079 | 73.93 ± 1.775 | 0.721 |
Sex (M/F), n (%) | 14/7(66.7/33.3) | 19/8(70.4/29.6) | 0.784 |
Temperature, °C, mean ± S D | 38.05 ± 0.95 | 37.89 ± 0.79 | 0.361 |
PaO2/FiO2 ratio, mmHg, mean ± SD | 201.19 ± 14.21 | 209.25 ± 11.08 | 0.65 |
White blood cell, 109/L, mean ± SD | 6.629 ± 0.807 | 6.613 ± 0.816 | 0.990 |
Neutrophils, 109/L, mean ± SD | 4.99 ± 0.78 | 5.43 ± 0.78 | 0.697 |
Lymphocyte, 109/L, mean ± SD | 0.67 ± 0.06 | 0.79 ± 0.08 | 0.17 |
Platelet, 109/L, mean ± SD | 178.57 ± 14.95 | 186.74 ± 14.93 | 0.69 |
CRP, mg/L, mean ± SD | 94.98 ± 13.69 | 88.76 ± 7.74 | 0.43 |
IL-6,pg/ml, mean ± SD | 60.69 ± 14.08 | 32.09 ± 7.37 | 0.06 |
Ferritin,μg/L, mean ± SD | 301.30 ± 60.75 | 220.43 ± 42.4 | 0.25 |
Creatine kinase, U/L, mean ± SD | 1.56 ± 0.15 | 1.75 ± 0.21 | 0.49 |
Creatinine, U/L, mean ± SD | 64.11 ± 3.61 | 73.89 ± 5.56 | 0.17 |
Alanine aminotransferase, U/L,mean ± SD | 25.37 ± 3.2 | 33.51 ± 5.2 | 0.22 |
Glutamate aminotransferase, mean ± SD | 27.13 ± 1.83 | 27.37 ± 2.37 | 0.93 |
Blood sugar, mmol/L, mean ± SD | 8.61 ± 0.87 | 8.53 ± 0.34 | 0.95 |
Cardiovascular disease, n (%) | 10(47.6%) | 13(48.1%) | 0.82 |
Diabetes, n (%) | 8(38.1%) | 10(37.0%) | 0.85 |
Respiratory disease, n (%) | 4(19.0%) | 5(18.5%) | 0.78 |
Neurologic disorder, n (%) | 6(28.6%) | 8(37.0%) | 0.70 |
hypertension, n (%) | 8(38.1%) | 14(51.8%) | 0.20 |
Primary and secondary clinical efficacy outcomes
Variable | Ventilator-free days, mean ± SD | 28-day mortality, n (%) | Days of temperature return to normal mean ± SD | Number of fungal infection n (%) |
---|---|---|---|---|
High-dose group | 12.19 ± 1.30 | 1(4.76%) | 2.00 ± 0.46 | 8(38.1%) |
Low-dose group | 13.92 ± 1.40 | 3(11.11%) | 4.48 ± 1.04 | 8(29.6%) |
t/ × 2 | 0.885 | 0.623 | 1.974 | 0.381 |
P-value | 0.38 | 0.43 | 0.04 | 0.53 |
Variable | High-dose group (21 patients) | Low-dose group (27 patients) | t | P-value |
---|---|---|---|---|
CRP mean ± SD | 27.44 ± 7.64 | 46.05 ± 4.37 | 1.707 | 0.01 |
IL-6mean ± SD | 19.46 ± 6.31 | 30.17 ± 9.41 | 1.143 | 0.02 |
Ferritin mean ± SD | 407.11 ± 80.69 | 368.04 ± 84.36 | -0.598 | 0.43 |